Selvom doserne af tidligere anvendt antimykotisk behandling for 5 af patienterne, der var inkluderet som refraktære, var lavere end de doser der ofte gives for invasiv aspergillose, var raterne af gunstigt respons under caspofunginbehandling for disse patienter magen til dem set for resten af de refraktære patienter (henholdsvis 2/ 5 og 17/ 48).
Although the doses of prior antifungal therapies in 5 patients enrolled as refractory were lower than those often administered for invasive aspergillosis, the favourable response rate during therapy with caspofungin was similar in these patients to that seen in the remaining refractory patients (2/ 5 versus 17/ 48, respectively).